IndicationsStatusPurposePhase
RecruitingTreatment1
clinicaltrials.gov IdentifierTitleDrugs
NCT02364609Pembrolizumab and Afatinib in Patients With Non-small Cell Lung Cancer With Resistance to Erlotinib